Biogen Inc. (BIIB) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Biogen Inc. stock price, BIIB
Biogen Inc. stock chart:
Biogen Inc. close price: 286.9
Stock price forecast:
UP TO +3.39%
Total forecasts: 90
Reached: 48 (53.33%)
Total Win: 312.28 (113.30%)
Showing 1-10 of 395 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Biogen Inc. latest news:
Investors see Biogen CEO choice as friendly to potential takeover
NEW YORK (Reuters) - The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.
BRIEF-Biogen's board approves separation of Bioverativ
* Biogen - for every 2 shares of co's common stock held of
record on Jan 17 2017, shareholders will receive one share of
Bioverativ common stock
Biogen shares slip following announcement of new CEO
Biogen Inc. shares slipped in the extended session Monday following a report, later confirmed by Biogen, that the biotech company will appoint a new chief executive. Biogen shares declined 0.6% to $277 after hours. Biogen said Chief Commercial Officer Michel Vounatsos will become CEO on Jan. 6, succeeding George Scangos, who has been CEO since 2010. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen shares slip on report of new CEO
Biogen Inc. shares slipped in the extended session Monday following a report that the biotech company is set to appoint a new chief executive. Biogen shares declined 1.2% to $275.50 after hours. Biogen is planning on announcing Chief Commercial Officer Michel Vounatsos as its new CEO to succeed George Scangos as early as this week, according to Reuters, citing people close to the matter.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Biogen shares rise 1.6% on leaked Alzheimer's drug data
iogen Inc. shares rose 1.6% in afternoon trade after data from its Alzheimer's drug was leaked. Biogen has been the particular target of investor interest after the recent high-profile failure of Eli Lilly's Alzheimer's drug. Biogen shares have dropped 5.5% year-to-date, compared with a 9.9% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors
Late-stage Alzehimer's drug failure could hurt Biogen, Merck. Eli Lilly and Company (LLY) shares plunged 11% Wednesday to a two-year low, after the company's treatment for people with mild dementia due to Alzheimer's disease failed to meet the primary endpoint in a late-stage clinical trial. The failure, which several Wall Street analysts said was disappointing, could have negative implications for Eli Lilly's Alzheimer's portfolio and competitors including Biogen Inc. and...
BioLife Solutions, Inc.BLFS
BioMarin Pharmaceutical Inc.BMRN
BiondVax Pharmaceuticals Ltd.BVXV
BiondVax Pharmaceuticals Ltd.BVXVW
Bio-Path Holdings, Inc.BPTH
BioShares Biotechnology Clinical Trials FundBBC
BioShares Biotechnology Products FundBBP